Analysis for the vancomycin plasma concentration data in infants by clinical pharmacists

doi:10.5246/jcps.2015.04.035

Abstract

Abstract:

In the present study, clinical pharmacists monitored the blood concentration of vancomycin in children in the Infant Ward from 2013 to 2014, and the drug dose was adjusted according to its plasma concentration. Moreover, we analyzed the plasma concentration of vancomycin in infants in the hospital from 2013 to 2014. Simultaneously, we also discussed the necessity of regular therapeutic drug monitoring of vancomycin in infants, and the important role of clinical pharmacists was further explored. The results showed that it was necessary to routinely monitor the therapeutic drug in infants. Clinical pharmacists performed medication monitoring, which improved the effectiveness of vancomycin and prevented its adverse effects. In addition, it is a new treatment model for the participation of clinical pharmacists in the clinical treatment.

Key words: Clinical pharmacists, Vancomycin, Infants, Therapeutic drug monitoring

CLC Number:

R969

Supporting:

Jinlian Zhang, Jia Zhou, Jihui Chen, Ting Chen, Yan Liu, Huaiping Tian, Jian Zhang. Analysis for the vancomycin plasma concentration data in infants by clinical pharmacists[J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(4): 263-266.

References

[1] Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J. Clin. Infect Dis. 2011, 52, 18-55.

[2] Holmes, N.E.; Turnidge, J.D.; Munckhof, W.J.; Robinson, J.O.; Korman, T.M.; O’Sullivan, M.V. Clin. Microbiol. Infect. 2013, 19, 1163-1168.

[3] Kim, S.H.; Kim, K.H.; Kim, H.B.; Kim, N.J.; Kim, E.C. Antimicrob. Agents Chemother. 2008, 52, 192-197.

[4] Stryjewski, M.E.; Szczech, L.A.; Benjamin, D.K.; Jr Inrig, J.K.; Kanafani, Z.A.; Engemann, J.J. Clin. Infect. Dis. 2007, 44, 190-196.

[5] Khatib, R.; Johnson, L.B.; Fakih, M.G.; Riederer, K.; Khosrovaneh, A.; Shamse, T.M. Scand. J. Infect. Dis. 2006, 38, 7-14.

[6] Matzke, G.R.; Zhanel, G.G.; Guay, D.R. Clin. Pharmacokinet. 1986, 11, 257-282.

[7] Matzke, G.R.; Mcgory, R.W.; Halstenson, C.E.; Keane, W.F. Antimicrob. Agents Chemother. 1984, 25, 433-437.

[8] Rodvold, K.A.; Blum, R.A.; Fischer, J.H.; Zokufa, H.Z.; Rotschafer, J.C.; Crossley, K.B. Antimicrob. Agents Chemother. 1988, 32, 848-852.

[9] Golper, T.A.; Noonan, H.M.; Elzinga. L.; Gilbert, D.; Brummett, R.; Anderson, J.L. Clin. Pharmacol. Ther. 1988, 43, 565-570.

[10] Li, D.; Shao, H. J. Chin. Pharm. Sci. 2009, 18, 354-357.

[11] Vandecasteele, S.J.; De Vriese, A.S. J. Antimicrob. Chemother. 2013, 68, 743-748.

[12] Roberts, J.A.; Lipman, J. Clin. Pharmacokinet. 2006, 45, 755-773.

[13] Lodise, T.P.; Lomaestro, B.; Graves, J.; Drusano, G.L. Antimicrob. Agents Chemother. 2008, 52, 1330-1336.

[14] Krivoy, N.; Peleg, S.; Postovsky, S.; Ben, M.W. Pediatr. Hematol. Oncol. 1998, 15, 333-338.

[15] Cao, Y.; Yang, W.; Lin, X.W.; Shao, H. J. Chin. Pharm. Sci. 2009, 18, 283-286.

[16] Chin J Infect Dis. 2012, 30, 641-646.

[17] Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; J Rybak, M.; Talan, D.A.; Chambers, H.F. Clin. Infect Dis. 2011, 52, 18-55.

[18] Rybak, M.; Lomaestro, B.; Rotschafer, J.C.; Moellering, R.J.; Craig, W.; Billeter, M.; Dalovisio, J.R.; Levine, D.P. Am. J. Health Sys. Pharm. 2009, 66, 82-98.

[19] Gilbert, D.N.; Moellering, R.C.; Eliopoulos, M.G.; Chambers, H.F.; Saag, M.S. Antimicrobial. Therapy Inc. 2010, 25-27.

[20] Wang, Y.; Song, X.; Xu, Q.; Zhang, H.N.; Xu, H. Chin. Hosp. Pharm. J. 2011, 31, 550-554.

[21] Bailie, G.R.; Neal, D. Med. Toxicol. Adverse Drug Exp. 1988, 3, 376-386.

[22] Griffith, R.S. Rev. Infect. Dis. 1981, 3, 200-204.

[23] Moellering, R.C. Clin. Infect. Dis. 2006, 42, 3-4.